Patients with atrial fibrillation receiving routine medical care within a large managed care organization were found to have suboptimal anticoagulation control. Retrospective cross-sectional study of ...

AP31969 is a novel, first-in-class, oral SK ion channel inhibitor intended for rhythm control of atrial fibrillation and has recently completed Phase 1 in healthy volunteers ...

HUYABIO International today announced favorable Phase 1 clinical data for HBI-3000, a novel bioinspired investigational drug with promising antiarrhythmic properties, excellent tolerability and a ...

Please provide your email address to receive an email when new articles are posted on . An updated guideline on the prevention and management of atrial fibrillation includes a new staging system to ...

Dr. Hugh Calkins answers the question: 'Atrial Fibrillation Meds Not Working?' — -- Question: I have tried four different heart rhythm medicines for atrial fibrillation and none of them seem to ...

A new research study, published in JAMA Cardiology, aimed to further confirm a previous correlation between asthma and atrial fibrillation (AF) and to determine if the degree of asthma control ...

The development of atrial fibrillation (AF) and atrial enlargement are intimately linked: persistent AF leads to atrial distension and, conversely, atrial enlargement in patients with hypertension or ...

There is a wide range of available treatments for atrial fibrillation. Patients may be entirely treated by their GP (general practitioner, primary care physician), while others may require the ...

Dose-response association seen between levels of asthma control and risk of atrial fibrillation (HealthDay News) — There is a correlation for asthma and lack of asthma control with the risk of atrial ...

Patients with newly diagnosed atrial fibrillation benefit from early rhythm control therapy, according to new results. Patients with newly diagnosed atrial fibrillation benefit from early rhythm ...

Acesion Pharma has begun enrolling patients into a phase 2 clinical trial of AP31969, its novel oral SK ion channel inhibitor being developed for rhythm control in atrial fibrillation.